Hypothesis

Maintaining NAD+ at youthful concentrations during cyclic OSK expression creates a metabolic checkpoint that biases epigenetic remodeling toward repair rather than oncogenic transformation. NAD+ fuels sirtuin deacetylases (SIRT1, SIRT6) that tighten chromatin, limit c‑Myc–driven transcriptional noise, and promote DNA‑damage response. When NAD+ falls, chromatin becomes hyper‑acetylated and permissive, allowing reprogramming factors to induce aberrant enhancer activation and pre‑cancerous epigenetic drift. Therefore, pharmacologically sustaining NAD+ will lower the Repair Capacity Index (RCI) decline and suppress tumor formation seen with OSK alone.

Mechanistic Rationale

1. NAD+‑Sirtuin Axis Controls Chromatin State – SIRT1 deacetylates H3K9ac and H3K56ac, fostering heterochromatin; SIRT6 deacetylates H3K9ac at telomeres and promoters of growth‑associated genes. Low NAD+ reduces sirtuin activity, increasing histone acetylation and chromatin openness, which is known to facilitate oncogenic transcription during reprogramming [3, 4].
2. c‑Myc Activity Is NAD+‑Sensitive – c‑Myc transcription is amplified when SIRT1 is inactive due to increased acetylation of c‑Myc and its co‑activators. NAD+ restoration re‑engages SIRT1‑mediated c‑Myc deacetylation, attenuating its oncogenic potency [5].
3. Epigenetic Clocks Detect Early Drift – Second‑generation clocks (PhenoAge) and multi‑omic frameworks (EpiAge‑R) capture shifts in methylation and repair capacity before histology [1, 2]. A falling Repair Capacity Index (RCI) would signal rising oncogenic risk during OSK cycles.
4. Budget‑Cut Analogy – The cell’s "ambition" to maintain youthful epigenome requires NAD+‑dependent energy. When NAD+ declines, the cell downregulates costly repair and fidelity mechanisms, akin to a budget cut that favors short‑term survival over long‑term integrity.

Experimental Design (Testable & Falsifiable)

• Model: Inducible OSK transgenic mice (pancreas, liver, kidney) with doxycycline‑pulsed dosing (2 days on/5 days off) for 3 months.
• Intervention: Daily oral NAD+ precursor (nicotinamide riboside, 300 mg/kg) vs vehicle control.
• Readouts:
  • Longitudinal measurement of DunedinPACE, PhenoAge, and EpiAge‑R‑derived RCI from blood and tissue biopsies every 2 weeks.
  • qPCR and Western blot for SIRT1/6 activity, acetyl‑H3K9, acetyl‑c‑Myc levels.
  • Histopathology and immunohistochemistry for dysplasia, neoplasia, and teratoma formation at endpoint.
  • RNA‑seq to detect ectopic activation of oncogenic enhancers.
• Predictions: NAD+‑supplemented mice will show (i) slower epigenetic age acceleration (lower ΔPace), (ii) higher RCI, (iii) reduced acetyl‑H3K9 and acetyl‑c‑Myc, and (iv) significantly lower tumor incidence (<10 % vs >40 % in controls).
• Falsification: If NAD+ supplementation fails to improve RCI, does not alter sirtuin activity or c‑Myc acetylation, and tumor rates remain indistinguishable from controls, the hypothesis is refuted.

Implications

This hypothesis reframes NAD+ not merely as a fuel but as a regulatory checkpoint that links cellular "ambition" to epigenetic safety. Successful validation would justify NAD+‑modulating adjuvants in clinical OSK‑based rejuvenation protocols, shifting the paradigm from blind boosting to dynamic, checkpoint‑guided dosing.